Home > Insider Trading > Filing (0000899243-23-014139)

Filing Details

Accession Number:: 0000899243-23-014139
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2023-05-30 21:54:16
Reporting Period:: 2023-05-25

Accepted Time:: 2023-05-30 21:54:16
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1528115	Annexon Inc.	ANNX	Pharmaceutical Preparations (2834)	275414423

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1687968	Bain Capital Life Sciences Fund, L.p.	200 Clarendon Street Boston MA 02116	No	No	Yes	No
1702921	Bcip Life Sciences Associates, Lp	200 Clarendon Street Boston MA 02116	No	No	Yes	No
1703030	Bain Capital Life Sciences Partners, Lp	200 Clarendon Street Boston MA 02116	No	No	Yes	No
1703031	Bain Capital Life Sciences Investors, Llc	200 Clarendon Street Boston MA 02116	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2023-05-25	300,000	$2.13	5,701,926	No	4	P	Indirect	See footnotes

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See footnotes

Footnotes

Represents 300,000 shares of Common Stock purchased by BCLS I Investco, LP ("BCLS I Investco") on May 25, 2023.
The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $2.08 to $2.25, inclusive. The reporting persons undertake to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.
Represents shares of Common Stock held by Bain Capital Life Sciences Fund, L.P. ("BCLS Fund I"), BCLS I Investco and BCIP Life Sciences Associates, LP ("BCIPLS" and, together with BCLS Fund I and BCLS I Investco, the "Bain Capital Life Sciences Entities"). Following the completion of the transactions reported in footnote (1) above, BCLS Fund I, BCLS I Investco and BCIPLS each holds 2,940,627, 2,460,298 and 301,001 shares of Common Stock, respectively.
Bain Capital Life Sciences Partners, LP ("BCLSP") is the general partner of BCLS Fund I. As a result, BCLSP may be deemed to share voting and dispositive power with respect to the securities held by BCLS Fund I. BCLSP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
BCLS I Investco GP, LLC ("BCLS I Investco GP"), whose manager is BCLS Fund I, is the general partner of BCLS I Investco. As a result, each of BCLSP, BCLS Fund I and BCLS I Investco GP may be deemed to share voting and dispositive power with respect to the securities held by BCLS I Investco. Each of BCLSP, BCLS Fund I and BCLS I Investco GP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.
Boylston Coinvestors, LLC is the general partner of BCIPLS.
Bain Capital Life Sciences Investors, LLC ("BCLSI") is the general partner of BCLSP and governs the investment strategy and decision making process with respect to investments held by BCIPLS. As a result, BCLSI may be deemed to share voting and dispositive power with respect to the securities held by the Bain Capital Life Sciences Entities. BCLSI disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.